Fig. 5.

Albendazole dose-response curves are altered by ugt-22 mutation and overexpression. (A) Percent rapid touch-responsive motility of adult ugt-22(gk411724lf) (lf, loss-of-function), wild type (N2), control line 1 (control transgenic array in a wild type background), ugt-22 OE line 3 (ugt-22 gDNA overexpression array in a wild type background), and ben-1(e1880) worms exposed to albendazole for 3 days. (B) EC₅₀ values, P-values, and EC₅₀ fold changes. Replicates equal 4–10 independent trials of ∼20–50 worms per trial. Note that wild type and ben-1 trials are the same in Fig. 2, Fig. 5.